0000000000115532

AUTHOR

Luis Rojas

showing 13 related works from this author

Impact of NADPH oxidase functional polymorphisms in acute myeloid leukemia induction chemotherapy.

2016

Efficacy and toxicity of anthracycline treatment in acute myeloid leukemia (AML) is mediated by reactive oxygen species (ROS). NADPH oxidase is the major endogenous source of ROS and a key mediator of oxidative cardiac damage. The impact of NADPH oxidase polymorphisms (CYBA:rs4673, NCF4:rs1883112, RAC2:rs13058338) was evaluated in 225 adult de novo AML patients. Variant alleles of NCF4 and RAC2 were related to higher complete remission (P=0.035, P=0.016), and CYBA homozygous variant showed lower overall survival with recessive model (P=0.045). Anthracycline-induced cardiotoxicity was associated to NCF4 homozygous variant (P=0.012) and CYBA heterozygous genotype (P=0.027). Novel associations…

0301 basic medicineMaleAnthracyclinePharmacologyBiologyPolymorphism Single NucleotideNephrotoxicity03 medical and health sciences0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsGeneticsHumansAgedRetrospective StudiesPharmacologychemistry.chemical_classificationReactive oxygen speciesCardiotoxicityNADPH oxidaseRemission InductionMyeloid leukemiaNADPH OxidasesInduction ChemotherapyMiddle Agedrac GTP-Binding ProteinsRac GTP-Binding ProteinsLeukemia Myeloid Acute030104 developmental biologychemistry030220 oncology & carcinogenesisToxicitybiology.proteinMolecular MedicineFemaleReactive Oxygen SpeciesThe pharmacogenomics journal
researchProduct

Positive impact of ABCB1 polymorphisms in overall survival and complete remission in acute myeloid leukemia: a systematic review and meta-analysis

2015

Positive impact of ABCB1 polymorphisms in overall survival and complete remission in acute myeloid leukemia: a systematic review and meta-analysis

0301 basic medicineOncologymedicine.medical_specialtyATP Binding Cassette Transporter Subfamily BPolymorphism Single Nucleotide03 medical and health sciencesRemission induction0302 clinical medicinehemic and lymphatic diseasesInternal medicinemental disordersGeneticsOverall survivalHumansMedicineSurvival ratePharmacologybusiness.industryRemission InductionComplete remissionMyeloid leukemiaSurvival RateLeukemia Myeloid Acute030104 developmental biology030220 oncology & carcinogenesisMeta-analysisMolecular MedicinebusinessThe Pharmacogenomics Journal
researchProduct

Influence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment

2017

Cytarabine is considered the most effective chemotherapeutic option in acute myeloid leukemia (AML). The impact of 10 polymorphisms in cytarabine metabolic pathway genes were evaluated in 225 adult de novo AML patients. Variant alleles of DCK rs2306744 and CDA rs602950 showed higher complete remission (p = .024, p = .045), with lower survival rates for variant alleles of CDA rs2072671 (p = .015, p = .045, p = .032), rs3215400 (p = .033) and wild-type genotype of rs602950 (p = .039, .014). Induction death (p = .033) and lower survival rates (p = .021, p = .047) were correlated to RRM1 rs9937 variant allele. In addition, variant alleles of CDA rs532545 and rs602950 were related to skin toxici…

Male0301 basic medicineOncologyCancer ResearchPharmacogenomic VariantsefficacyKaplan-Meier Estimatepolymorphism0302 clinical medicinePolymorphism (computer science)GenotypeRemission InductionCytarabineDCKMyeloid leukemiaHematologyMiddle AgedPrognosisLeukemia Myeloid AcuteOncology030220 oncology & carcinogenesisToxicityFemaleMetabolic Networks and Pathwaysmedicine.drugAdultAntimetabolites Antineoplasticmedicine.medical_specialtyAdolescentGenotypeacute myeloid leukemiaPolymorphism Single NucleotideYoung Adult03 medical and health sciencesInternal medicinemedicineMucositisHumansAlleleAllelesAgedRetrospective StudiesPolymorphism Geneticbusiness.industrymedicine.diseaseMinor allele frequency030104 developmental biologyCDAImmunologyCytarabinebusiness
researchProduct

Association of SNPs with the efficacy and safety of immunosuppressant therapy after heart transplantation.

2015

Aim: Studying the possible influence of SNPs on efficacy and safety of calcineurin inhibitors upon heart transplantation. Materials & methods: In 60 heart transplant patients treated with tacrolimus or cyclosporine, we studied a panel of 36 SNPs correlated with a series of clinical parameters during the first post-transplantation year. Results: The presence of serious infections was correlated to ABCB1 rs1128503 (p = 0.012), CC genotype reduced the probability of infections being also associated with lower blood cyclosporine concentrations. Lower renal function levels were found in patients with rs9282564 AG (p = 0.003), related to higher blood cyclosporine blood levels. A tendency tow…

AdultGraft RejectionMalemedicine.medical_specialtyATP Binding Cassette Transporter Subfamily Bmedicine.medical_treatmentRenal functionSingle-nucleotide polymorphismInfectionsKidneyKidney Function TestsGastroenterologyPolymorphism Single NucleotideTacrolimusInternal medicineGenotypeGeneticsmedicineHumansAgedPharmacologyHeart transplantationGraft rejectionbusiness.industryMiddle AgedTacrolimusTissue DonorsCalcineurinImmunologyCyclosporineMolecular MedicineHeart TransplantationFemalebusinessPharmacogeneticsImmunosuppressive AgentsPharmacogenomics
researchProduct

Meta-analysis and systematic review of the effect of the donor and recipient CYP3A5 6986A>G genotype on tacrolimus dose requirements in liver tran…

2013

Objective A meta-analysis was carried out of publishedstudies on the effect of the CYP3A5 6986A>Gpolymorphism in liver donors and transplant recipientson tacrolimus pharmacokinetics.Methods Cohort studies that evaluated the relationshipbetween the CYP3A5 polymorphism in liver donors andtransplant recipients and tacrolimus, trough bloodconcentration normalized for the daily dose (C) perkilogram body weight (D) (C/D, ng/ml/mg/kg/day) up to1 year after transplantation, were included. Data were notrestricted by patient age or the language or journal ofpublication. A literature search was conducted using theCochrane Library, MEDLINE, EMBASE, and grey literature,and articles published up to 24 Ap…

Adultmedicine.medical_specialtyAdolescentGenotypemedicine.medical_treatmentLiver transplantationPolymorphism Single NucleotideGastroenterologyTacrolimusYoung AdultInternal medicineGenotypeLiving DonorsGeneticsCytochrome P-450 CYP3AHumansMedicineGeneral Pharmacology Toxicology and PharmaceuticsCYP3A5Molecular BiologyGenetics (clinical)AgedAged 80 and overTransplantationbusiness.industryGenetic VariationMiddle AgedTacrolimusLiver TransplantationTransplantationMeta-analysisImmunologyMolecular MedicinebusinessImmunosuppressive AgentsPharmacogeneticsCohort studyPharmacogenetics and Genomics
researchProduct

SNPs and taxane toxicity in breast cancer patients

2014

Aim: In order to identify genetic variants associated with taxanes toxicity, a panel with 47 SNPs in 20 genes involved in taxane pathways was designed. Patients & methods: Genomic DNA of 113 breast cancer patients was analyzed (70 taking docetaxel, 43 taking paclitaxel). Results: Two SNPs associated with docetaxel toxicity were identified: CYP3A4*1B with infusion-related reactions; and ERCC1 Gln504Lys with mucositis (p ≤ 0.01). Regarding paclitaxel toxicity: CYP2C8 HapC and CYP2C8 rs1934951 were associated with anemia; and ERCC1 Gln504Lys with neuropathy (p ≤ 0.01). Conclusion: Genes involved in DNA repair mechanisms and reactive oxygen species levels influence taxane toxicity in cance…

Bridged-Ring CompoundsMucositisOncologymedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsPaclitaxelmedicine.medical_treatmentBreast NeoplasmsDocetaxelPharmacologyPolymorphism Single Nucleotidechemistry.chemical_compoundBreast cancerInternal medicineGeneticsMucositisCytochrome P-450 CYP3AHumansMedicineGenetic Association StudiesAgedPharmacologyChemotherapyTaxanebusiness.industryCancerMiddle AgedEndonucleasesmedicine.diseaseDNA-Binding ProteinsDocetaxelPaclitaxelchemistryMolecular MedicineFemaleTaxoidsERCC1businessmedicine.drugPharmacogenomics
researchProduct

PKP-020 Impact of nadph oxidase functional polymorphisms in acute myeloid leukaemia induction chemotherapy

2016

Background NADPH oxidase, a key mediator of oxidative cardiac damage and remodelling, modulates anthracycline clinical cardiotoxicity. Purpose Single nucleotide polymorphisms (SNPs) of NADPH oxidase genes could lead to interindividual differences in treatment outcome in acute myeloid leukaemia (AML) patients. Material and methods The main three NADPH oxidase polymorphisms (CYBA:rs4673, NCF4:rs1883112 and RAC2:rs13058338) were evaluated in 225 adult patients at the initial diagnosis of AML using a mass spectrometry based multiplex genotyping assay (Sequenom). All patients received induction chemotherapy consisting of idarubicin plus cytarabine (PETHEMA 99, 2007 and 2010 trials). The efficacy…

Oncologymedicine.medical_specialtyCardiotoxicityNADPH oxidasebiologyAnthracyclinebusiness.industryInduction chemotherapySingle-nucleotide polymorphismInternal medicineGenotypeImmunologymedicinebiology.proteinCytarabineIdarubicinGeneral Pharmacology Toxicology and Pharmaceuticsbusinessmedicine.drugEuropean Journal of Hospital Pharmacy
researchProduct

A systematic review and meta-analysis of the impact of WT1 polymorphism rs16754 in the effectiveness of standard chemotherapy in patients with acute …

2015

The polymorphism rs16754 of the WT1 gene has been described as a possible prognostic marker in different acute myeloid leukemia (AML) cohorts; however, it is not supported by all the studies. We performed the first meta-analysis evaluating the effect of this polymorphism upon the effectiveness of standard AML therapy. Fourteen cohort studies were included (3618 patients). Patients with the variant allele showed a significant higher overall survival (OS) at 5 years (OR: 1.24, 95% CI: 1.06-1.45, P = 0.007, with dominant model). WT1 did not influence complete remission, but a higher disease-free survival was observed with the variant allele. In the subgroup analysis, Caucasians, pediatric and …

Oncologymedicine.medical_specialtySubgroup analysisPolymorphism Single NucleotideCohort Studies03 medical and health sciences0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsGeneticsmedicineHumansIdarubicinAnthracyclinesWT1 ProteinsGenetic Association StudiesEtoposideSurvival analysisEtoposidePharmacologybusiness.industryCytarabineMyeloid leukemiaSurvival AnalysisLeukemia Myeloid AcuteObservational Studies as Topic030220 oncology & carcinogenesisMeta-analysisImmunologyCytarabineMolecular Medicinebusiness030215 immunologymedicine.drugCohort studyThe Pharmacogenomics Journal
researchProduct

PKP-003 Influence of cytarabine metabolic pathway polymorphisms in effectiveness of acute myeloid leukaemia induction treatment

2017

Background Cytarabine is considered the most effective chemotherapeutic agent in the treatment of acute myeloid leukaemia (AML). Purpose Several studies suggest that single nucleotide polymorphisms (SNPs) in genes involving the metabolic pathway of cytarabine could influence treatment outcomes, although their clinical relevance remains undetermined. Material and methods The SNPs of cytarabine pathway (DCK:rs2306744, rs11544786, rs4694362; CDA:rs2072671, rs3215400, rs532545, rs602950; NT5C2:rs11598702; RRM1:rs9937; NME1:rs2302254) were evaluated in 225 adult patients at initial diagnosis of AML using a mass spectrometry based multiplex genotyping assay (Sequenom). All patients received induc…

OncologyCreatininemedicine.medical_specialtyeducation.field_of_studybusiness.industryPopulationInduction chemotherapySingle-nucleotide polymorphismchemistry.chemical_compoundchemistryInternal medicineGenotypeImmunologyCytarabinemedicineIdarubicinClinical significanceeducationbusinessmedicine.drugPharmacokinetics and pharmacodynamics
researchProduct

PKP-005 Prognostic impact of novel gene polymorphisms in newly diagnosed acute myeloid leukaemia adults undergoing induction chemotherapy: Abstract P…

2015

Background Single nucleotide polymorphisms (SNPs) could lead to inter-individual differences in treatment outcomes. Purpose A recent study 1 reported several novel SNPs involved in cytarabine cytotoxicity using a whole-genome approach, which were associated with clinical outcomes in a paediatric AML population. However their association with effectiveness and toxicity remain undetermined in adults. Material and methods The six SNPs with clinical significance in the Gamazon study 1 (Table 1) were evaluated in 109 adult patients at initial diagnosis with AML using a mass spectrometry–based multiplex genotyping assay (Sequenom). All patients were treated with idarubicin plus cytarabine. Genoty…

Oncologymedicine.medical_specialtyeducation.field_of_studybusiness.industryPopulationInduction chemotherapySingle-nucleotide polymorphismNeutropeniamedicine.diseaseInternal medicineGenotypeImmunologyCytarabinemedicineClinical significanceGeneral Pharmacology Toxicology and PharmaceuticsAllelebusinesseducationmedicine.drugEuropean Journal of Hospital Pharmacy
researchProduct

Influence of ABCB1 polymorphisms upon the effectiveness of standard treatment for acute myeloid leukemia: A systematic review and meta-analysis of ob…

2015

The ABCB1 gene encodes for P-glycoprotein (P-gp), an efflux pump for a variety of xenobiotics. The role of ABCB1 polymorphisms in acute myeloid leukemia (AML) outcomes of standard chemotherapy (cytarabine plus anthracyclines) remains controversial. A systematic search was made of studies evaluating the association between ABCB1 polymorphisms 1236C>T, 2677G>T/A and 3435C>T and effectiveness variables. We found seven cohort studies (1241 patients) showing a significantly higher overall survival (OS) among carriers of the variant allele of 1236C>T at year 4 (odds ratio (OR): 1.47, 95% confidence interval (CI): 1.07-2.01), 2677G>T/A at years 4-5 (OR: 1.37, 95% CI: 1.01-1.86) and 3435C>T at year…

AdultMaleOncologymedicine.medical_specialtyATP Binding Cassette Transporter Subfamily BAdolescentSubgroup analysisCohort StudiesYoung AdultInternal medicineGeneticsmedicineHumansAnthracyclinesChildAgedAged 80 and overPharmacologyGeneticsPolymorphism Geneticbusiness.industryStandard treatmentCytarabineInfantMyeloid leukemiaOdds ratioMiddle AgedConfidence intervalLeukemia Myeloid AcuteObservational Studies as TopicTreatment OutcomeChild PreschoolMeta-analysisCytarabineMolecular MedicineFemalebusinessmedicine.drugCohort studyThe Pharmacogenomics Journal
researchProduct

Impact ofABCsingle nucleotide polymorphisms upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia

2016

Anthracycline uptake could be affected by efflux pumps of the ABC family. The influence of 7 SNPs of ABC genes was evaluated in 225 adult de novo acute myeloid leukemia (AML) patients. After multivariate logistic regression there were no significant differences in complete remission, though induction death was associated to ABCB1 triple variant haplotype (p = .020). The ABCB1 triple variant haplotype was related to higher nephrotoxicity (p = .016), as well as this haplotype and the variant allele of ABCB1 rs1128503, rs2032582 to hepatotoxicity (p = .001; p = .049; p  .001). Furthermore, the variant allele of ABCC1 rs4148350 was related to severe hepatotoxicity (p = .044), and the variant al…

Male0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyGenotypePharmacogenomic Variantsmedicine.medical_treatmentSingle-nucleotide polymorphismNeutropeniaBiologyPolymorphism Single Nucleotide03 medical and health sciences0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansIdarubicinProspective cohort studyAllelesAgedRetrospective StudiesAged 80 and overChemotherapyHaplotypeInduction chemotherapyMyeloid leukemiaInduction ChemotherapyHematologyMiddle Agedmedicine.diseaseLeukemia Myeloid AcuteTreatment Outcome030104 developmental biologyAmino Acid SubstitutionOncology030220 oncology & carcinogenesisImmunologyATP-Binding Cassette TransportersFemaleBiomarkersmedicine.drugLeukemia & Lymphoma
researchProduct

Effect of CYP3A5*3 on kidney transplant recipients treated with tacrolimus: a systematic review and meta-analysis of observational studies

2014

The highly variable pharmacokinetics of tacrolimus can hamper the optimal management of kidney transplant patients. This variability has been attributed to the genetic polymorphism of CYP3A5 6986A>G, but the evidence is not clear. We conducted a meta-analysis of studies evaluating the effect of CYP3A5 polymorphism on kidney transplant recipients with tacrolimus plasma concentration divided by daily dose per body weight (C/D) and clinical outcomes. We searched in MEDLINE and EMBASE. We found evidence suggesting a significantly lower C/D among CYP3A5*1 allele carriers compared with carriers of the CYP3A5*3/*3 genotype at weeks 1 and 2, and months 1, 3, 6 and 12. We demonstrated that the expre…

Graft Rejectionmedicine.medical_specialtyPharmacologyGastroenterologyKidney transplantTacrolimusPharmacokineticsInternal medicineGenotypeGeneticsmedicineCytochrome P-450 CYP3AHumansAlleleCYP3A5Pharmacologybusiness.industryKidney TransplantationTransplant RecipientsTacrolimusObservational Studies as Topicsurgical procedures operativeMeta-analysisMolecular MedicineObservational studybusinessImmunosuppressive Agents
researchProduct